Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9291 Phase II in T790M-positive NSCLC (China)
CTR20150537Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Jul 2015; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20150537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150537.